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Nonalcoholic fatty liver disease (NAFLD) defines a wide spectrum of liver diseases that extend from simple steatosis, that is,
increased hepatic lipid content, to nonalcoholic steatohepatitis (NASH), a condition that may progress to cirrhosis with its
associated complications. Nuclear hormone receptors act as intracellular lipid sensors that coordinate genetic networks regulating
lipid metabolism and energy utilization. This family of transcription factors, in particular peroxisome proliferator-activated
receptors (PPARs), represents attractive drug targets for the management of NAFLD and NASH, as well as related conditions
such as type 2 diabetes and the metabolic syndrome. The impact on the regulation of lipid metabolism observed for PPARs has
led to the hypothesis that genetic variants within the human PPARs genes may be associated with human disease such as NAFLD,
the metabolic syndrome, and/or coronary heart disease. Here we review the available evidence on the association between PPARs
genetic polymorphism and the susceptibility to NAFLD and NASH, and we provide a meta-analysis of the available evidence.
The impact of PPAR variants on the susceptibility to NASH in specific subgroup of patients, and in particular on the response to
therapies, especially those targeting PPARs, represents promising new areas of investigation.
1. Introduction
Nonalcoholic fatty liver disease (NAFLD), a major cause of
progressive liver disease, is defined by an increase in hepatic
fat content not related to toxics and has a strong genetic
component. As the peroxisome proliferator-activated recep-
tors (PPARs) represent major regulators of lipid metabolism
in the liver, a few studies have tested the hypothesis that
genetic variants in these hormone receptors may influence
the susceptibility toNAFLD, but with controversial results. In
this paper, we provide an overview of the published evidence
in the field, and a meta-analysis of the available results on the
role of the Pro12Ala PPAR𝛾 single nucleotide polymorphism
(SNP), the most studied genetic variant to date. As PPARs
are also the target of several drugs under evaluation for the
treatment ofNAFLD, this evidencemay lay the basis to design
pharmacogenetic studies to assess the role of PPARs SNPs
in predicting the response to drugs targeting these nuclear
receptors.
2. Nonalcoholic Fatty Liver Disease (NAFLD)
Liver fat deposition related to systemic insulin resistance (IR)
defines NAFLD [1]. The acronym NAFLD defines a wide
spectrum of liver disease ranging from simple uncomplicated
hepatic fat accumulation in the form of triglycerides exceed-
ing 5% of liver mass in the absence of significant alcohol
consumption to severe steatohepatitis characterized by severe
steatosis, lobular inflammation, and hepatocellular damage
and apoptosis with the activation of fibrogenesis [2], which
can progress to cirrhosis and hepatocellular carcinoma [3].
Due to the epidemic of obesity and the metabolic syndrome,
NAFLD is now the most frequent liver disease (prevalence
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20–34%) and the leading cause of altered liver enzymes in
Western countries [4, 5]. Hepatic fat accumulation results
from an unbalance between triglycerides acquisition and
removal [6] and initially represents a protective mechanism
to shield hepatocytes from the toxicity resulting from an
increased flux of free fatty acids (FFAs) to the liver [7].
Several lines of evidence support the hypothesis that most
of the FFAs accumulated as triglycerides during steatosis
derive from increased peripheral lipolysis [8] related to
adipose tissue IR [9], followed by increased lipogenesis
induced by hyperinsulinemia and diet. Indeed, themajor risk
factor for NAFLD is represented by systemic IR related to
central obesity and the metabolic syndrome [1, 10]. Steato-
sis per se may then precipitate hepatic IR contributing to
metabolic disturbances and cardiovascular damage [11, 12].
Impaired ability to secrete lipoproteins [13] and decreased
𝛽-oxidation due to mitochondrial damage (in particular in
the presence of NASH) may also play a role in hepatic fat
accumulation.
Epidemiological, familial, and twin studies have recently
provided clear evidence for an element of heritability of
NAFLD [14–16]. During the last years, genetic modifiers of
disease severity and progression have been identified through
genome-wide association studies [17, 18]. These include the
Patatin-like phospholipase domain-containing 3 (PNPLA3)
I148M gene variant, which has been demonstrated to repre-
sent a major determinant of interindividual and ethnicity-
related differences in hepatic fat content independent of IR
and serum lipid concentration, and a determinant of the pro-
gression towards NASH and fibrosis [19, 20]. Furthermore,
a few large multicenter case-control studies demonstrated a
role of SNPs implicated in insulin signalling [21], oxidative
stress [22], and fibrogenesis [23] in the progression of
NAFLD towards NASH confirming that hepatocellular fat
accumulation and IR are key operative mechanisms in the
pathophysiology of NAFLD and are closely involved in the
progression of liver damage. New genetic risk factors could
prove useful for the clinical management of patients with
NAFLD and for the identification of novel therapeutic targets
for NASH, for which specific treatments are still lacking.
3. Peroxisome Proliferator-Activated
Receptors: The PPARs
The PPARs represent novel targets for the development of
therapeutic agents for the treatment of metabolic syndrome,
obesity, dyslipidemia and type 2 diabetes. Nuclear receptors
are transcription factors that serve as intracellular receptors
for endocrine hormones and dietary lipids. Differently from
extracellular receptorswhich bind to peptide ligands and acti-
vate cytoplasmic kinase cascades, nuclear receptors interact
directly with lipophilic ligands and regulate the expression
of target genes [26]. These receptors can be considered the
body’s lipid sensor that can monitor the concentration of
bioactive lipids and coordinate the enzymatic cascades that
regulate lipid synthesis and utilization.There are three mem-
bers of the PPAR family each encoded by a different gene:
PPAR𝛼 (NR1C1), PPAR𝛾 (NR1C3), and PPAR𝛿 (NP1C2).
All three PPARs bind to DNA as heterodimers with the
retinoid X receptor (RXR).
4. PPAR𝛼
PPAR𝛼directly regulates a network of genes encoding protein
involved in fatty acids uptake, enzymes required for the
oxidation of fatty acids (𝛽-oxidation), and enzymes required
for ketogenesis by binding to control regions in the promoter
of these genes and by promoting fat utilization [27]. The
net effect is increased fatty acids oxidation, decreased serum
triglycerides, and an increase in cholesterol efflux. PPAR𝛼
is predominantly expressed in tissues capable of oxidizing
fatty acids such as liver, heart, muscle, brown adipose tissue,
and the kidney. PPAR𝛼 can be activated by natural lipophilic
ligands such as fatty acids and by drugs approved for the
treatment of hypertriglyceridemia, such as fibrates [28]. The
role of PPAR𝛼 in the pathogenesis of fatty liver became
evident in PPAR𝛼 KO mice. These mice are unable to upreg-
ulate fatty acid catabolism and develop steatosis, myocardial
lipid accumulation, and hypoglycaemia during short-term
starvation or after high-fat diet [29, 30]. Taken together,
mousemodels suggest that PPAR𝛼 functions to increase fatty
acid use in the fasting state, and that in the context of a high-
fat diet PPAR𝛼, inducing fatty acid catabolism, might prevent
hepatocellular fat accumulation and hypertriglyceridemia.
PPAR𝛼 downregulation is involved inNASH pathogenesis by
reducing FFA catabolism [31].
5. PPAR𝛼 Polymorphisms and NAFLD
The role of PPAR𝛼 gene polymorphisms in NAFLD and the
regulation of lipid metabolism has been investigated in a few
studies. Chen et al. hypothesized that the coding Val227Ala
SNP in the PPAR𝛼 gene may be implicated in the pathogene-
sis of NAFLD. In 79 NAFLD patients and 63 healthy controls,
it was found that the PPAR𝛼 Val227Ala genotype frequency
was significantly different between NAFLD and control sub-
jects and that the fat-related index such as weight, body mass
index (BMI), hip circumference, waist circumference, waist-
to-hip ratio, and the percentage of body fat of the carriers
of the Ala227 allele was lower than that in noncarriers [24].
Yamakawa-Kobayashi et al. evaluated the Val227Ala SNP in
401 healthy Japanese subjects. Total cholesterol was lower in
Ala227 carriers than in noncarriers, and the lipid profiles
of Ala227 carriers appeared favourable compared with those
of non-carriers. Since the Val227Ala variant is located in
the region between the DNA-binding and ligand-binding
domains, which is also thought to contain the dimerisation
domain of the protein, it has been hypothesized that the
substitution of Valine to Alanine at codon 227 causes a
functional change in PPAR𝛼, and that the Ala227 isoform has
higher activity than the Val227 isoform [32], thus leading to
enhanced ability to burn fatty acids, and potentially explain-
ing the association with lower lipid levels and the protection
from steatosis development.However, Sparsø et al. genotyped
the Leu162Val SNP in the PPAR𝛼 gene in 5799 middle-
aged white people, but they did not find any association
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Table 1: Characteristics of the studies on the association between the PPAR𝛼 polymorphisms and nonalcoholic fatty liver disease.
First author, year Ref. PPAR𝛼variant
Population ethnicity,
country
Sample size
(𝑁)
Patients
characteristics
Liver biopsy
(𝑁)
Female
sex,𝑁 (%) Conclusions
Chen, 2008 [24] Val227Ala China 𝑁 = 79 UnspecifiedNAFLD
𝑁 = not
specified 40 (51)
Association with
NAFLD
Dongiovanni, 2010 [25] Leu162Val Caucasian, Italy 𝑁 = 202 HistologicalNAFLD 𝑁 = 202 41 (20)
No association with
NAFLD
Ref: reference number;𝑁: number; NAFLD: nonalcoholic fatty liver disease.
with obesity or type 2 diabetes. Though, another PPAR𝛼
coding polymorphism, the Leu162Val variant, was possibly
associated with increased fasting cholesterol and triglyceride
concentrations [33]. The relationship between the Leu162Val
SNP andNAFLDwas further evaluated in 202 Italian subjects
compared to 346 healthy controls. The frequency of this
SNP did not differ between patients and controls, but the
presence of the PPAR𝛼 162Val allele was associated with
higher IR, but not histologically assessed disease severity
[25], suggesting that the risk related to increased IR may
be balanced by the protective effect of decreased oxidative
stress, the other key player in the progression of liver disease
in patients with NASH. Results of the published association
studies between PPAR𝛼 polymorphisms and NAFLD are
summarized in Table 1.
6. PPAR𝛾
PPAR𝛾 is the master regulator of adipogenesis and plays an
important role in the process of lipid storage [34]. PPAR𝛼 and
PPAR𝛾 have therefore opposing functions in the regulation of
fat metabolism; PPAR𝛼 promotes fat utilization while PPAR𝛾
promotes fat storage. PPAR𝛾 is expressed in adipocytes,
macrophages, and muscle, where it regulates development,
lipid homeostasis, and glucose metabolism. Mice lacking
PPAR𝛾 are embryonically lethal, but the development of
conditional PPAR𝛾 knockouts has confirmed the essential
role of PPAR𝛾 in adipocytes differentiation and survival
[35]. Moreover, specific deletion of PPAR𝛾 in fat and muscle
causes IR underlying its importance in peripheral insulin
sensitivity [36]. Possible mechanisms underlying the insulin
sensitizing activity of PPAR𝛾 include increased lipid uptake
and storage leading to decreased free fatty acids and serum
triglycerides, induction of the expression of adiponectin,
a molecule with anti-inflammatory and insulin-sensitizing
effect by adipocytes [37], and the suppression of hepatic
gluconeogenesis and increased glucose uptake by adipose
tissue through GLUT4 upregulation [38]. Fatty acids and
prostanoids act as PPAR𝛾 agonists. However, also the thia-
zolidinediones (TZDs), a class of insulin sensitizers that are
approved for the treatment of type 2 diabetes and have been
shown to decrease steatosis in patients with NASH [39, 40],
function as high affinity PPAR𝛾 agonists. The activation of
PPAR𝛾 by TZDs induces the expression of a set of genes
involved in adipocytes differentiation and lipogenesis and
induces adiponectin, thus explaining the insulin-sensitizing
action of these drugs [41, 42].
7. Role of PPAR𝛾 Polymorphisms:
Rationale and Available Studies
Human genetics has provided evidence of a role of PPAR𝛾 in
the metabolic syndrome [43]. Dominant negative mutations
in PPAR𝛾 are the cause of a monogenic disease characterized
by severe insulin resistance, type 2 diabetes, and hypertension
[44]. Importantly, a frequent coding SNP in the PPAR𝛾 gene,
the Pro12Ala variant, has consistently been associated in
metabolic studies with BMI, insulin sensitivity, the metabolic
syndrome [45]. The N-terminal proline to alanine exchange
(Pro12Ala) occurs in the extra domain of the PPAR𝛾2
transcript: this PPAR𝛾 splice isoform includes 30 additional
amino acids [46], which are responsible for an increase of
PPAR𝛾 transcriptional activity in the adipose tissue. The
Pro12Ala exchange results from a cytosine to guanine substi-
tution in the PPAR𝛾 gene, encoding the Ala allele form with
a strongly reduced function [47]. The association between
the positivity for the 12Ala variant and IR, type 2 diabetes,
higher BMI, and obesity has already been well described and
confirmed in several studies [48–50]. This association may
be explained by the lower activity of the 12Ala variant in the
adipose tissue, favouring IR and potentially the flux of FFAs
to the liver and NAFLD. However, the role of this SNP in
the pathogenesis and progression of fatty liver disease is still
debated.
Rey et al. analyzed the presence of the Pro12Ala polymor-
phism in 622 German Caucasian subjects suffering from fatty
liver (263 NAFLD patients and 100 with alcoholic fatty liver
disease (AFLD) subjects) or being healthy blood donors (𝑛 =
259). In fatty liver disease patients the Ala allele was more
represented than in controls. In NAFLD patients the higher
prevalence of the 12Ala allele was not associated with the
progression of liver disease, whereas AFLD patients carrying
the 12Ala allele had a higher risk of severe steatohepatitis
and fibrosis [53]. Similarly, the 12Ala allele was not associated
with NAFLD susceptibility, liver damage, or IR in 212 Italian
patients withNAFLD [25]. Gupta et al. analyzed the genotype
frequencies of the Pro12Ala variant in 98 NAFLD patients
and 280 matched controls and found a higher prevalence of
heterozygosity for the Ala variant in patients. Moreover, in
NAFLD patients the 12Ala variant was also associated with
overweight (BMI > 25Kg/m2), suggesting an important role
of Pro12Ala variant in the obesity-related NAFLD disease
pathogenesis [52]. Gawrieh et al. investigated the association
between two PPAR𝛾 variants (the Pro12Ala and a second
common SNP, the C1431T) with NAFLD and its histological
features. They considered 212 patients with NAFLD and 63
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Table 2: Characteristics of the studies on the association between the Pro12Ala variant of PPAR𝛾 and nonalcoholic fatty liver disease.
First author, year Ref. Ethnicity,country
Study design,
sample size (𝑁) Patients characteristics
Liver biopsy
(𝑁)
Female
sex,𝑁 (%)
Dongiovanni, 2010 [25] Caucasian,Italy
Case-control
𝑁 = 202
Histologically proven NAFLD 𝑁 = 202 41 (20)
Gawrieh, 2011 [51] Caucasian,USA
Case-control
𝑁 = 212
Histologically proven NAFLD 𝑁 = 212 145 (68)
Gupta, 2011 [52] Asian,India
Case-control
𝑁 = 98
Diagnosis based on ultrasound 𝑁 = 71 32 (33)
Rey, 2010 [53] Caucasian,Germany
Case-control
𝑁 = 263
Histologically proven NAFLD 𝑁 = 263 Notspecified
Yang, 2012 [54] Asian,China
Case-control
𝑁 = 436
Diagnosis based on ultrasound — 280 (64)
Ref: reference number;𝑁: number; NAFLD: nonalcoholic fatty liver disease.
controls and found that individual SNPs did not show
significant association with NAFLD. The haplotype defined
by the presence of both minor alleles (GT) was less enriched,
whereas an haplotype, comprised of the two major alleles
(CC), was more enriched in subjects with NAFLD compared
to controls, and both haplotypes were significantly associated
with steatosis and fibrosis [51]. As the carriers of the 12Ala
variant have been reported to have increased resistance
to oxidative stress [55], and since smoking increases the
production of reactive oxygen species, Yang et al. explored
the influence of the Pro12Ala SNP on the risk of NAFLD
and determined whether this polymorphism and smoking
showed a synergistic effect on the development of NAFLD
in middle-aged and older Chinese people (considering 436
NAFLD patients and 467 controls). The 12 Pro/Pro genotype
and smoking were significant independent risk factor for
NAFLD. In addition, the higher risk group (smokers with
the 12 Pro/Pro genotype) showed 3.75 times higher risk of
NAFLD than the low-risk group (nonsmokers with the 12
Pro/Ala genotype). However, no relationship between the
PPAR𝛾 gene and grading for steatohepatitis was observed.
They hypothesized a possible synergistic effects of genotype
and smoking in the development of NAFLD by aggravating
oxidative stress [54]. Zhou et al. investigated the association
of seven candidate SNPs with susceptibility to NAFLD in
117 Chinese patients and matched controls and found that
the genotypic distributions and allelic frequencies of the
PPAR𝛾 gene −161 C/T polymorphism in the NAFLD group
were significantly different from those in the control group
suggesting that the C/T variant increased the susceptibility to
NAFLD [56]. Finally, very recently Bhatt et al. have investi-
gated the associations of polymorphisms C161T and Pro12Ala
of PPAR𝛾 with clinical and biochemical parameters in 162
Asian patients with ultrasonographically diagnosed NAFLD
and 173 controls. They found that the Pro12Ala polymor-
phism was associated with significantly higher serum TG,
alkaline phosphatase, and waist-hip ratio, whereas the C161T
polymorphism with increased TG and total cholesterol. At
multivariate analysis, NAFLD was associated with these two
polymorphisms [57].
8. A Meta-Analysis of Available Studies on
the Association between PPAR Pro12Ala
Variant and NAFLD
In view of the still controversial evidence concerning the
association between PPAR𝛾 genotype and NAFLD suscep-
tibility mentioned above, we decided to estimate from the
available literature the strength of the effect of Pro12Ala vari-
ant of PPAR𝛾 gene on NAFLD across different populations.
In contrast, due to the heterogeneity of geneticmarkers evalu-
ated in previous studies, it was not possible to conduct ameta-
analysis of PPAR𝛼 studies. For the electronic searches, pub-
lished studies were found through PubMed at the National
Library of Medicine (http://ncbi.nlm.nih.gov/entrez/query/)
for the query NAFLD, PPAR𝛾 polymorphism, and Pro12Ala
variant (rs1801282). References list in relevant publications
was also considered.The literature searchwas done on studies
up to 2012, written in English and for which were available
abstracts and complete article. For the meta-analysis we
considered five papers, which are presented in Table 2. There
were not country restrictions. The presence of NAFLD was
diagnosed by biopsy or ultrasound. All the studies were
population-based case-control studies. Complete or partial
information about liver biopsy was available in four studies,
and data about fatty liver was analyzed in 1238 subjects with
NAFLD. Genotyping for rs18012282 was carried out using
TaqMan allelic discrimination in three studies [52–54] and
by polymerase chain reaction (PCR) and restriction analysis
in two studies [25, 52]. The calculations were performed
using the free meta-analysis REV Manager 5.0 Software
Informer (http://ims.cochrane.org/revman/). Results of the
meta-analysis are presented in Figure 1. This meta-analysis,
by summarizing the amount of evidence, failed to detect
a significant association between the Pro12Ala SNP in the
PPAR𝛾 gene and NAFLD, highlighting at the same time a
significant heterogeneity among the published studies.
In line with this result, no genome-wide association
studies found an association between genomic variants in
PPARs genes and NAFLD. Moreover, the majority of studies
indicate that the Pro12Ala variant is especially involved in
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1 10 1000.10.01
12Pro/Pro 12Ala positive
Study
12Ala positive 12Pro/Pro
Weight
Odds ratio Oddsratio
Events Total Events Total
Mantel-Haenszel, random
(95% conﬁdenceinterval)
Mantel-Haenszel, random
(95% conﬁdenceinterval)
Dongiovanni 36 87 166 461 20.9% 1.25 (0.8–2.0)
Gawrieh 15 117 18 62 15.9% 0.36 (0.2–0.8)
Gupta 35 102 63 276 20.4% 1.77 (1.1–1.9)
Rey 57 116 206 406 21.8% 0.94 (0.6–1.4)
Yang 30 88 406 815 21.0% 0.53 (0.3–0.8)
Total (95% c.i.) 510 2020 100% 0.86 (0.5–1.4)
tal events 173 859
Heterogeneity: Tau2 = 0.25, Chi2 = 19.9, df = 4 (P = 0.0005); I2 = 80%
Testforoveralle ffect: Z = 0.59(P = 0.56)
Figure 1: Meta-analysis of the effect of the Pro12Ala PPAR𝛾 variant on the risk of NAFLD in published studies.The odds ratio (ORs) and the
corresponding 95% confidence interval (c.i.) limits (lower and upper) are calculated by random effects meta-analysis (Mantel-Haenszel; M-
H) for nonalcoholic fatty liver disease (NAFLD) according to the Pro12Ala variant (12Ala positive versus 12Pro/Pro genotype). In the “Study”
is cited the first author of the study. “Events” indicate the number of patients with NAFLD who carry a genotype (e.g., 36 positive for 12Ala
allele) while “Total” indicates the sum of patients and controls with the same genotype (e.g., 87 is the sum of NAFLD patients and controls
who carry the 12 allele). In the graph, numbers indicate OR and filled diamond express random effect. The symbol size is proportional to the
weight of the study.
the development of type 2 diabetes. However, it is possible
that the Pro12Ala polymorphism in the PPAR𝛾 gene may
contribute to the pathogenesis of NAFLD in the presence of
other genetic variants or in the presence of environmental
risk factors, such as obesity. Therefore, future studies should
be conducted in larger series of well-characterized patients
with a homogenous clinical subphenotype of NAFLD (e.g.,
in severely obese patients) and should be controlled for
other major risk factors for NAFLD, such as the I148M
PNPLA3 variant. In conclusion, the Pro12Ala variant cannot
be considered a clinically relevantmarker for NAFLD, at least
when evaluated alone in the overall population. Despite this,
as we aremoving towards individualizedmedicine, these data
could provide the basis to design pharmacogenetic studies
to address whether therapeutic efficacy of PPAR𝛾 agonists
in NAFLD patients is affected by the 12Ala SNP alone or
in combination with other SNPs of genes involved in lipid
metabolism, and whether PPAR SNPs may modify NAFLD
risk in specific populations.
9. PPAR𝛿
PPAR𝛿 is ubiquitously expressed, most highly in brain,
macrophages, lung, adipose tissue, and skeletal muscle [26,
58] and is activated by fatty acids and components of very-
low-density lipoprotein (VLDL) [28, 59]. PPAR𝛿 activation
enhances fatty acids transport and oxidation, improves glu-
cose homeostasis via the inhibition of hepatic glucose output,
reduces macrophages inflammatory responses, and increases
HDL levels [60]. PPAR𝛿 knockout mice die in midgestation.
Surviving mice show markedly decreased adipose tissue
suggesting a requirement for PPAR𝛿 in peripheral tissues
[61]. Further support for a role of PPAR𝛿 in lipoprotein
metabolism results from studied exploring the activity of
the PPAR𝛿 specific synthetic agonist GW501516. Treatment
of animals including primates with GW501516 significantly
increases HDL, lowers triglycerides, and LDL and decreases
fasting insulin levels [62, 63]. Synthetic PPAR𝛿 agonists have
proven to be effective also in preclinical model of diabetes
and dyslipidemia, and preliminary results are also available
for steatosis. Results of a two-week phase II study in patients
with dyslipidemia demonstrated that total cholesterol, LDL
cholesterol, triglycerides, and nonesterified fatty acids were
significantly lowered by GW501516 [64]. The impact on the
regulation of lipid and carbohydratemetabolism observed for
PPAR𝛿 has led to the hypothesis that genetic variation within
the human PPAR𝛿 gene may be associated with human
disease such as the metabolic syndrome and/or coronary
heart disease. The +294 T/C polymorphism in exon 4 of the
PPAR𝛿 gene seems to influence binding of Sp-1 resulting
in higher transcriptional activity for the rare C allele than
the common T allele [65]. Skogsberg et al. observed in 543
healthy, middle-agedmen that the C genotype was associated
with elevated levels of LDL cholesterol and ApoB [66]. In
580 male subjects with hyperlipidemia recruited from the
West of Scotland Coronary Prevention Study (WOSCOPS)
carriers of the C allele had significantly lower HDL plasma
concentrations [67], whereas Aberle et al. found a highly
significant association between the rare C allele and lower
plasma HDL concentrations in 967 females with mixed
hyperlipidemia [68]. Robitaille et al. identified 15 variants
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in the PPAR𝛿 gene and found that another polymorphism
(−87 T > C) was associated with a lower risk to exhibit the
metabolic syndrome and that this association was influenced
by dietary fat intake [69]. Andrulionyte et al. found that SNPs
of the PPAR𝛿 gene may modify the conversion from IGT to
type 2 diabetes particularly in combination with Gly482Ser
SNP of the PPAR𝛾 coactivator-1A (PGC-1A) and Pro12Ala
SNP of PPAR𝛾2 [70]. Grarup et al. investigated variation
in PPAR𝛿 gene in 6071 Danish white subjects of whom
4543 had NGT, 503 had IFG, 693 had IGT, and 352 had
diabetes. They concluded that common variation in PPAR𝛿
does not affect the risk of metabolic disease in the popula-
tion studied [71]. However, no published study specifically
addressed the role of PPAR𝛿 SNPs in the susceptibility to
NAFLD.
10. Conclusions
Available studies do not provide sufficient evidence for a
significant evidence for an association between PPAR𝛼 and
PPAR𝛾 SNPs, and the risk of NAFLD. In particular, our
meta-analysis of the effect of the Pro12Ala PPAR𝛾2 SNP,
the best studied genetic factor to date, and NAFLD did not
provide conclusive results. However, most of the studies were
underpowered, the definition of the NAFLD phenotype was
rather heterogeneous (histological versus ultrasonographic
versus based on liver enzymes), the analyses were conducted
in ethnically diverse population, and most studies were not
controlled for other genetic risk factor for NAFLD such as
the PNPLA3 I148M SNP, so that the patients included were
not phenotypically homogeneous. Furthermore, even scarcer
data are available for the association of PPARs variantwith the
progression of liver damage, and variants of PPAR𝛿, another
nuclear receptor involved in IR and lipid metabolism, were
not assessed. Most importantly, PPARs are promising targets
for NASH, but no study has yet assessed the effect of genetic
variants in PPARs genes and the effect of therapy.
The evaluation of the impact of PPAR variants on (1) the
susceptibility to NASH in specific subgroup of patients such
as severely obese subjects in adequately powered studies and
(2) on the response to drugs targeting PPARs (such as glita-
zones or PPAR𝛼/𝛿 agonists, which are under study in NASH
patients), represent promising new areas of investigation.
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